Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy.
BACKGROUND
To evaluate the association between the clinical, dosimetric factors and severe acute radiation pneumonitis (SARP) in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT).


METHODS
We analyzed 94 LANSCLC patients treated with concurrent chemotherapy and IMRT between May 2005 and September 2006. SARP was defined as greater than or equal 3 side effects and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The clinical and dosimetric factors were analyzed. Univariate and multivariate logistic regression analyses were performed to evaluate the relationship between clinical, dosimetric factors and SARP.


RESULTS
Median follow-up was 10.5 months (range 6.5-24). Of 94 patients, 11 (11.7%) developed SARP. Univariate analyses showed that the normal tissue complication probability (NTCP), mean lung dose (MLD), relative volumes of lung receiving more than a threshold dose of 5-60 Gy at increments of 5 Gy (V5-V60), chronic obstructive pulmonary disease (COPD) and Forced Expiratory Volume in the first second (FEV1) were associated with SARP (p < 0.05). In multivariate analysis, NTCP value (p = 0.001) and V10 (p = 0.015) were the most significant factors associated with SARP. The incidences of SARP in the group with NTCP > 4.2% and NTCP <or=4.2% were 43.5% and 1.4%, respectively (p < 0.01). The incidences of SARP in the group with V10 <or=50% and V10 >50% were 5.7% and 29.2%, respectively (p < 0.01).


CONCLUSIONS
NTCP value and V10 are the useful indicators for predicting SARP in NSCLC patients treated with concurrent chemotherapy and IMRT.
Shi
Anhui
A
Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Zhu
Guangying
G
Wu
Hao
H
Yu
Rong
R
Li
Fuhai
F
Xu
Bo
B
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000209:etiology; D017564:Radiation Pneumonitis / Q000175:diagnosis / Q000209:etiology*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D016896:Treatment Outcome
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):106-13
12694828
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407
16997503
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):650-9
11597805
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):1-9
9747813
Strahlenther Onkol. 2003 Dec;179(12):823-31
14652671
Radiother Oncol. 2004 May;71(2):175-81
15110451
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):329-39
12243805
Eur J Cancer. 1998 Jan;34(1):71-5
9624240
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1258-67
15001271
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):65-75
7642433
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):410-6
17236964
Ann Oncol. 1995 Sep;6(7):693-7
8664191
Clin Oncol (R Coll Radiol). 2002 Oct;14(5):361-6
12555874
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):561-2
9336132
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9
10487552
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):39-45
9989512
Radiother Oncol. 1997 Jul;44(1):17-22
9288852
Radiology. 2005 Apr;235(1):208-15
15703313
J Clin Oncol. 1999 Sep;17(9):2692-9
10561343
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):89-94
10924976
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):110-5
12504042
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78
9806503
Strahlenther Onkol. 2003 Aug;179(8):548-56
14509954
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):563-70
9336133
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1355-63
15817337
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):94-102
17321067
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):125-31
16427214
Radiother Oncol. 1998 Jul;48(1):61-9
9756173
Radiother Oncol. 2003 Jun;67(3):275-83
12865175
Semin Radiat Oncol. 2003 Jul;13(3):176-81
12903007